Venus Medtech Hosts Inaugural Global Partner Summit in Paris
Company highlights international growth strategy, expanding structural heart portfolio, and commercialization priorities PARIS, May 26, 2026 /PRNewswire/ -- Venus Medtech convened its inaugural Global Partner Summit in Paris under the theme...
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company")...
Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations
HONG KONG, April 22, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced financial results for the year...